IRTC IRhythm Technologies Inc.

iRhythm® Technologies Continues to Fuel Innovation in Cardiac Monitoring and Unveils Two FDA Clearances for Superior Patient Care

iRhythm® Technologies Continues to Fuel Innovation in Cardiac Monitoring and Unveils Two FDA Clearances for Superior Patient Care

The new Zio® monitor is designed to significantly improve patient comfort, while enhanced AI capabilities raise the bar on cardiac arrhythmia detection

SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced two new 510K clearances – one for a new and improved design of its flagship monitor and a second for updated artificial intelligence (AI) capabilities. The new Zio monitor is designed to significantly improve patient comfort while the advancements to its AI capabilities will further improve rhythm and beat diagnostic accuracy. The clearances demonstrate the company’s ongoing commitment to improving the patient and provider experience – by investing in next-generation capabilities across its diagnostic platform.

“iRhythm’s new Zio monitor and enhanced AI further illustrates our commitment to raising the standard of cardiac care for the providers and patients we serve,” said Mike Coyle, CEO of iRhythm. “By improving patient comfort and experience we can continue to maximize patient compliance, which is an essential element for collecting high-quality data for analysis. And with the power of our next generation AI, we can help physicians better identify, diagnose and manage a wide array of significant arrhythmias, including atrial fibrillation.”

The new Zio monitor: The new Zio monitor is designed to be effortless to wear with increased adherence and better patient comfort. It’s small enough for patients to forget they are wearing it through exercise, showering, and sleeping. The new design is more than 50% lighter than the current generation and includes a new breathable and waterproof outer layer. It also has an improved ‘stay-put’ adhesive and a more flexible design for a secure attachment. These refinements will allow for a more comfortable wear and, therefore, more complete, accurate diagnostic data.

“iRhythm started with the patient in mind first,” said Judy Lenane, RN, Chief Clinical Officer and Executive Vice President of Products at iRhythm. “We asked ourselves what it would take to give patients the best, most comfortable experience, and designed it from there. We’re excited to offer more patients around the world access, as well as an improved patient experience, which will enable far more insight into the data.”

Enhanced AI: iRhythm has made significant system improvements to its deep-learned AI algorithm. The company has collected over 750 million hours of curated heartbeat data, creating the largest repository of labelled ECG patient data in the world. This allows for expanded training of the algorithm across a larger database, resulting in enhanced AI diagnostic accuracy and better quality assurance. On top of the record expansion, iRhythm now has a much more technologically advanced AI backbone – moving from machine-learned to deep-learned capabilities. With AI, the average rhythm detection sensitivity of iRhythm’s detection algorithm has improved by 21% since its creation in 2010.

iRhythm has led the cardiac monitoring industry in using FDA-cleared, deep-learned algorithms for classifying and characterizing diverse heart rhythms. iRhythm is now using AI to detect beats, beat types and heart rates – on top of the deep-learned rhythm detection capability introduced and clinically validated in 2019. This allows for AI-based detection of heart activity at a much more granular level, with an enhanced level of accuracy.

“With this clearance, we are excited to be further improving on our AI-based detection capabilities, raising the bar for the cardiac monitoring industry,” said Mark Day, Executive Vice President of Research and Development at iRhythm. “This new AI algorithm will enable the Zio Service to be even more accurate and scalable, delivering more clinical insight for cardiologists and payers.”

The updated AI capabilities will be introduced later this quarter for the US-based Zio Service, while the new Zio monitor platform will begin limited release later this year.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Investor Relations Contact

Leigh Salvo

(415) 937-5404





Media Contact

Morgan Mathis

(310) 528-6306

A photo accompanying this announcement is available at



EN
24/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 5,000 shares at 175.000USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial ...

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhythm’s Zio long-term continuous monitoring (LTCM) device and service could improve diagnosis of atrial fibrillation (AFib) in 5040 participants in the United ...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)Morgan Stanley Global Healthcare Conference 2025 on Tuesday, September 9, 2025, at 2:35 p.m. Eastern Time (11:35 a...

 PRESS RELEASE

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm...

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service’s value across patient populations and payer segments. SAN FRANCISCO, Aug....

 PRESS RELEASE

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution f...

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a digital health leader focused on creating trusted solut...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch